{"DataElement":{"publicId":"5914123","version":"1","preferredName":"Solid Neoplasm Immune-Modified Response Evaluation Criteria in Solid Tumors Best Overall Response Type","preferredDefinition":"Text code to represent the best overall disease response in solid tumors since the beginning of the study, using iRECIST response criteria.","longName":"IRECIST_BEST_OVR_TYP","context":"DCI","contextVersion":"1","DataElementConcept":{"publicId":"5914122","version":"1","preferredName":"Solid Neoplasm Immune-Modified Response Evaluation Criteria in Solid Tumors Best Overall Response","preferredDefinition":"A benign or malignant neoplasm arising from tissues that do not include fluid areas.  Representative examples include epithelial neoplasms (e.g. lung carcinoma, prostate carcinoma, breast carcinoma, colon carcinoma), and neoplasms arising from the soft tissues and bones (e.g. leiomyosarcoma, liposarcoma, chondrosarcoma, osteosarcoma).  Neoplasms originating from the blood or bone marrow (leukemias and myeloproliferative disorders) are not considered solid tumors._A modification of the Response Evaluation Criteria in Solid Tumors (RECIST), version 1.1, for use as a standard approach to solid tumor measurements and definitions for objective change in tumor size in cancer clinical trials in which an immunotherapy is used._The most clinically favorable response recorded from the start of the study treatment until the end of treatment.","longName":"3838551v1.0:5914109v1.0","context":"DCI","contextVersion":"1","ObjectClass":{"publicId":"3838551","version":"1","preferredName":"Solid Neoplasm","preferredDefinition":"Cancer of body tissues other than blood, bone marrow, or the lymphatic system.","longName":"C9292","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Solid Neoplasm","conceptCode":"C9292","definition":"A benign or malignant neoplasm arising from tissues that do not include fluid areas.  Representative examples include epithelial neoplasms (e.g. lung carcinoma, prostate carcinoma, breast carcinoma, colon carcinoma), and neoplasms arising from the soft tissues and bones (e.g. leiomyosarcoma, liposarcoma, chondrosarcoma, osteosarcoma).  Neoplasms originating from the blood or bone marrow (leukemias and myeloproliferative disorders) are not considered solid tumors.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":"NCI Thesaurus","workflowStatus":"RELEASED","registrationStatus":"Application","id":"E34BBF24-FC56-768F-E040-BB89AD4334A3","latestVersionIndicator":"Yes","beginDate":"2013-08-06","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2013-08-06","modifiedBy":"ONEDATA","dateModified":"2013-08-06","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"Property":{"publicId":"5914109","version":"1","preferredName":"Immune-Modified Response Evaluation Criteria in Solid Tumors Best Overall Response","preferredDefinition":"A modification of the Response Evaluation Criteria in Solid Tumors (RECIST), version 1.1, for use as a standard approach to solid tumor measurements and definitions for objective change in tumor size in cancer clinical trials in which an immunotherapy is used.:The most clinically favorable response recorded from the start of the study treatment until the end of treatment.","longName":"C136711:C94536","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Immune-Modified Response Evaluation Criteria in Solid Tumors","conceptCode":"C136711","definition":"A modification of the Response Evaluation Criteria in Solid Tumors (RECIST), version 1.1, for use as a standard approach to solid tumor measurements and definitions for objective change in tumor size in cancer clinical trials in which an immunotherapy is used.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Best Overall Response","conceptCode":"C94536","definition":"The most clinically favorable response recorded from the start of the study treatment until the end of treatment.","evsSource":"CTCAE_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"54A0A9D6-33C0-6B42-E053-F662850AEA6A","latestVersionIndicator":"Yes","beginDate":"2017-07-18","endDate":null,"createdBy":"HARTLEYG","dateCreated":"2017-07-18","modifiedBy":"ONEDATA","dateModified":"2017-07-18","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"ConceptualDomain":{"publicId":"2008550","version":"1","preferredName":"Disease Response","preferredDefinition":"the response criteria (includes RECIST and others) and associated documentation of disease.","longName":"DZ_RESP","context":"CTEP","contextVersion":"2.31","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B22C0651-216B-5273-E034-0003BA12F5E7","latestVersionIndicator":"Yes","beginDate":"2002-12-19","endDate":null,"createdBy":"MSUPLEY","dateCreated":"2002-12-19","modifiedBy":"SBR","dateModified":"2003-10-29","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"54A0C8BD-13EE-4731-E053-F662850AFAC7","latestVersionIndicator":"Yes","beginDate":"2017-07-18","endDate":null,"createdBy":"HARTLEYG","dateCreated":"2017-07-18","modifiedBy":"HARTLEYG","dateModified":"2017-07-21","changeDescription":"Curated to support Immunotherapy Response Protocol","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"ValueDomain":{"publicId":"5895897","version":"1","preferredName":"Immune-Modified Response Evaluation Criteria in Solid Tumors Type","preferredDefinition":"Something distinguishable as an identifiable class based on common qualities.","longName":"IRECIST_TYPE","context":"NCI Standards","contextVersion":"1","type":"Enumerated","dataType":"CHARACTER","minLength":null,"maxLength":"7","minValue":null,"maxValue":null,"decimalPlace":null,"PermissibleValues":[{"value":"NE","valueDescription":"Unevaluable","ValueMeaning":{"publicId":"3855538","version":"1","preferredName":"Unevaluable","longName":"3855538","preferredDefinition":"Unable to be evaluated.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Unevaluable","conceptCode":"C62222","definition":"Unable to be evaluated.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"E3F3FD8B-328D-C859-E040-BB89AD43580F","latestVersionIndicator":"Yes","beginDate":"2013-08-14","endDate":null,"createdBy":"COOPERM","dateCreated":"2013-08-14","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"53BAF5DA-7109-75C8-E053-F662850AED93","beginDate":"2017-07-07","endDate":null,"createdBy":"HARTLEYG","dateCreated":"2017-07-07","modifiedBy":"ONEDATA","dateModified":"2017-07-07","deletedIndicator":"No"},{"value":"iCPD","valueDescription":"Progressive Disease, Confirmed","ValueMeaning":{"publicId":"5895898","version":"1","preferredName":"Progressive Disease, Confirmed","longName":"5895898","preferredDefinition":"Having been established or verified.: A disease process that is increasing in scope or severity.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Confirmation","conceptCode":"C25458","definition":"Having been established or verified.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Progressive Disease","conceptCode":"C35571","definition":"A clinical, pathologic, and/or molecular finding indicating that the course of a disease is worsening in terms of extent or severity.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"53BAF5DA-7116-75C8-E053-F662850AED93","latestVersionIndicator":"Yes","beginDate":"2017-07-07","endDate":null,"createdBy":"HARTLEYG","dateCreated":"2017-07-07","modifiedBy":"HARTLEYG","dateModified":"2018-04-24","changeDescription":"User curated long name to support DCI, Modified RANO, ghd, 04.24.18","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"53BAF5DA-712F-75C8-E053-F662850AED93","beginDate":"2017-07-07","endDate":null,"createdBy":"HARTLEYG","dateCreated":"2017-07-07","modifiedBy":"ONEDATA","dateModified":"2017-07-07","deletedIndicator":"No"},{"value":"iUPD","valueDescription":"Unconfirmed Progressive Disease","ValueMeaning":{"publicId":"5895900","version":"1","preferredName":"Unconfirmed Progressive Disease","longName":"5895900","preferredDefinition":"A disease process that is increasing in scope or severity but the criteria for progressive disease is not met.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Unconfirmed Progressive Disease","conceptCode":"C123607","definition":"A disease process that is increasing in scope or severity but the criteria for progressive disease is not met.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"53BAF5DA-713C-75C8-E053-F662850AED93","latestVersionIndicator":"Yes","beginDate":"2017-07-07","endDate":null,"createdBy":"HARTLEYG","dateCreated":"2017-07-07","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"53BAF5DA-7155-75C8-E053-F662850AED93","beginDate":"2017-07-07","endDate":null,"createdBy":"HARTLEYG","dateCreated":"2017-07-07","modifiedBy":"ONEDATA","dateModified":"2017-07-07","deletedIndicator":"No"},{"value":"iSD","valueDescription":"Stable Disease","ValueMeaning":{"publicId":"2560100","version":"1","preferredName":"Stable Disease","longName":"2560100","preferredDefinition":"Cancer that is neither decreasing nor increasing in extent or severity.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Stable Disease","conceptCode":"C18213","definition":"A disease that is neither decreasing nor increasing in extent or severity.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE87-B7D1-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2002-02-13","endDate":null,"createdBy":"SBR","dateCreated":"2002-02-13","modifiedBy":"KUMMEROA","dateModified":"2022-09-13","changeDescription":"Manually curated for OHSU 10262","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"53BAF5DA-7169-75C8-E053-F662850AED93","beginDate":"2017-07-07","endDate":null,"createdBy":"HARTLEYG","dateCreated":"2017-07-07","modifiedBy":"ONEDATA","dateModified":"2017-07-07","deletedIndicator":"No"},{"value":"iPR","valueDescription":"Partial Remission","ValueMeaning":{"publicId":"3854969","version":"1","preferredName":"Partial Remission","longName":"3854969","preferredDefinition":"A finding indicating that there is a decrease in the size and the extent of tissue involvement by a malignant tumor in a patient.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Partial Remission","conceptCode":"C18058","definition":"A finding indicating that there is a decrease in the size and the extent of tissue involvement by a malignant tumor in a patient.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"E3DF4512-86B4-A83E-E040-BB89AD431C6D","latestVersionIndicator":"Yes","beginDate":"2013-08-13","endDate":null,"createdBy":"COOPERM","dateCreated":"2013-08-13","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":"Manually curated for OHSU 10262.","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"53BAF5DA-717D-75C8-E053-F662850AED93","beginDate":"2017-07-07","endDate":null,"createdBy":"HARTLEYG","dateCreated":"2017-07-07","modifiedBy":"ONEDATA","dateModified":"2017-07-07","deletedIndicator":"No"},{"value":"iCR","valueDescription":"Complete Remission","ValueMeaning":{"publicId":"3951936","version":"1","preferredName":"Complete Remission","longName":"3951936v1.00","preferredDefinition":"The disappearance of all signs of cancer in response to treatment.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Complete Remission","conceptCode":"C4870","definition":"The disappearance of all signs of cancer in response to treatment.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"EB155E17-C5DA-CEC3-E040-BB89AD4342C2","latestVersionIndicator":"Yes","beginDate":"2013-11-13","endDate":null,"createdBy":"COOPERM","dateCreated":"2013-11-13","modifiedBy":"SOKKERL","dateModified":"2023-04-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"53BAF5DA-7191-75C8-E053-F662850AED93","beginDate":"2017-07-07","endDate":null,"createdBy":"HARTLEYG","dateCreated":"2017-07-07","modifiedBy":"ONEDATA","dateModified":"2017-07-07","deletedIndicator":"No"}],"ConceptualDomain":{"publicId":"2008550","version":"1","preferredName":"Disease Response","preferredDefinition":"the response criteria (includes RECIST and others) and associated documentation of disease.","longName":"DZ_RESP","context":"CTEP","contextVersion":"2.31","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B22C0651-216B-5273-E034-0003BA12F5E7","latestVersionIndicator":"Yes","beginDate":"2002-12-19","endDate":null,"createdBy":"MSUPLEY","dateCreated":"2002-12-19","modifiedBy":"SBR","dateModified":"2003-10-29","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"RepresentationTerm":{"publicId":"2234813","version":"1","preferredName":"Type","preferredDefinition":"Type; a subdivision of a particular kind of thing.","longName":"C25284","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Type","conceptCode":"C25284","definition":"Something distinguishable as an identifiable class based on common qualities.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":"NCI Thesaurus","workflowStatus":"RELEASED","registrationStatus":"Standard","id":"F970CDF6-F90E-21D3-E034-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2005-06-14","endDate":null,"createdBy":"CAMPBELB","dateCreated":"2005-06-14","modifiedBy":"SBR","dateModified":"2005-09-08","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"53BAF5DA-70EB-75C8-E053-F662850AED93","latestVersionIndicator":"No","beginDate":"2017-07-07","endDate":null,"createdBy":"HARTLEYG","dateCreated":"2017-07-07","modifiedBy":"KNABLEJ","dateModified":"2019-07-19","changeDescription":"10/22/18 tmt Transferred from DCI to NCI Standards context as part of RECIST FG content.  Changes should not be made to this VD without coordinating with DCI/Duke (Michael D. Leonard, Annie Tsui, Michael Goodin).Curated to support Immunotherapy Response Protocol","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"ClassificationSchemes":[],"AlternateNames":[],"ReferenceDocuments":[{"name":"iRECIST Best Overall Response","type":"Preferred Question Text","description":"iRECIST Best Overall Response","url":null,"context":"DCI"},{"name":"Theradex - 1","type":"Alternate Question Text","description":"iRecist Response Assessment","url":null,"context":"Theradex"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"54A13125-DDC3-7B9E-E053-F662850A5059","latestVersionIndicator":"Yes","beginDate":"2017-07-18","endDate":null,"createdBy":"HARTLEYG","dateCreated":"2017-07-18","modifiedBy":"TAYLORT","dateModified":"2017-10-30","changeDescription":"Curated to support Immunotherapy Response Protocol","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"}}